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Medium-ring analogues of dibenzodiazepines by 
conformationally induced Smiles ring expansion 
 Romain Costil, Quentin Lefebvre, and Jonathan Clayden*[a] 
 
Abstract: Analogues of dibenzodiazepines in which the 7-
membered nitrogen heterocycle is replaced by a 9-12 membered 
ring were made by an unactivated Smiles rearrangement of 5-8 
membered heterocyclic anthranilamides. The conformational 
preference of the tertiary amide in the starting material leads to 
intramolecular migration of a range of aryl rings, even those lacking 
electron-withdrawing activating groups, and provides a method for 
n→n+4 ring expansion. The medium-ring products adopt a chiral 
ground state with an intramolecular, transannular hydrogen bond. 
The rate of interconversion of their enantiomeric conformations 
depends on solvent polarity. Ring-size and adjacent steric hindrance 
enables the modulation of this ‘hidden hydrophilicity’, making this 
scaffold a good candidate for drug development. 
Approaches to drug design have recently started employing 
shape-based 3D molecular descriptors in an effort to “escape 
from flatland”,[1] with good success in the prediction of the 
likeliness of clinical success.[1b,1c] Medium-sized rings (with 8 to 
12 atoms) present promising scaffolds for the development of 
small-molecule drugs with an extended three-dimensional shape. 
The limited flexibility of these rings is beneficial for enhanced 
binding affinity, while their well-defined conformations ameliorate 
physicochemical properties such as bioavailability or cell 
permeability.[2] Nonetheless it is well established that 
unfavourable transannular interactions increase the enthalpy of 
transition states of reactions leading to medium rings.[3] This 
makes their synthesis difficult,[4] and consequently medium rings 
are under-represented in screening libraries.[2b,5] Only recently, 
some medium-ring lactams have been found active against 
myelogenous leukemia,[6a] while trapoxins and apicidins, two 
classes of cyclotetrapeptides isolated from fungi, are anti-
protozoal agents that function by inhibition of histone 
deacetylase.[6b,6c]  
Dibenzodiazepine tricyclic antidepressants (TCAs, 
Scheme 1) are widely prescribed for the treatment of depression, 
schizophrenia, or nocturnal enuresis.[7] Dibenzodiazepines 
possess a pair of rigid but rapidly interconverting enantiomeric 
“butterfly” conformations, arising from the strain in the dibenzo-
fused 7-membered heterocycle.[8] This interconversion is locked 
in telenzepine, of which one of the two atropisomers is 500 times 
more active than the other.[9] 
 
Scheme 1. Prototypical tricyclic antidepressants and our approach to their 
medium-ring analogues. 
Ring expansion provides an appealing way to make medium-
sized heterocyclic rings, because transannular strain is to some 
extent mitigated in the transition state leading to the medium 
ring,[2b,10] and because heterocycles of rings sizes 5-7 are readily 
available. In this paper we report the use of an unconventional 
variant of the Smiles rearrangement[11] to generate medium rings 
from much simpler benzo-fused nitrogen heterocycles by n→n+4 
ring expansion.[12] The work builds on our observation[13] that the 
usual electron-withdrawing activating substituents are not 
necessary for the Smiles rearrangement of tertiary anilides, 
because conformational preorganization[14] about the N–CO 
bond is sufficient to place the nucleophilic migration terminus 
and the electrophilic aromatic ring in close proximity. Scheme 1 
shows the overall strategy, and illustrates the similarity of the 
reaction products to ring-expanded analogues of the biologically 
active dibenzodiazepines.  
Anthranilamides 3 were made efficiently by condensation 
of isatoic anhydride derivatives 1 with nitrogen heterocycles 2 
(See the Supporting Information for details).[15] Compound 3b, 
for example, was obtained in one step from a mixture of N-
methyl isatoic anhydride and tetrahydroquinoline in THF in the 
presence of a base. On treatment with NaHMDS in refluxing 
THF, 3b rearranged to the migration product 4b, having a ten-
membered ring, in 40% yield (Table 1, entry 1). Increasing the 
temperature to 100 °C (in a sealed tube) improved the yield of 
the product (entry 2), but also led to decomposition to the 
corresponding N-methyl anthranilic acid and tetrahydroquinoline 
(THQ, Table 1, final column). Microwave heating promoted a 
cleaner reaction, giving the product in 72% yield after only 15 
min (entry 3). KHMDS gave comparable results (entry 5), but 
there was negligible conversion with LiHMDS. Silazide bases 
seem particularly suited for this ring expansion as other bases 
investigated were either too weak, leaving the starting material 
untouched, or too nucleophilic, leading to decomposition (entry 
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6). 2-Methyl THF provided a good alternative solvent, giving the 
product in 67% isolated yield (entry 4), whereas toluene and 
MTBE led to decomposition (see Supporting Information). 
 
Table 1. Optimisation of the reaction conditions. 
 
Entry Base T / °C t 
Isolated yield 
4b / % 
Recovered 
THQ[a] /%[b] 
1 NaHMDS 66 16 h 40[b] 38 
2 NaHMDS 100 15 min[c] 66 22 
3 NaHMDS 100 15 min[d] 72 <5 
4 NaHMDS 100 15 min[d] 67[e] <5 
5 KHMDS 100 15 min[d] 62[b] <5 
6 LiHMDS 100 15 min[d] 2[b],[f] <5 
Reaction conditions: 3b (0.11 mmol, 1.0 eq.), with base (1.1 eq.) in THF (0.2 
M). [a] THQ = 1,2,3,4-tetrahydroquinoline. [b] 1H NMR yields determined using 
1,3,5-trimethoxybenzene as internal standard. [c] Using a sealed tube. [d] 
Using a microwave reactor. [e] 2-MeTHF as solvent. [f] No product obtained 
with Phosphazene base P4-tBu, 1,5,7-Triazabicyclo[4.4.0]dec-5-ene (TDB) or 
KOtBu as base. 
Having identified the optimal conditions for rearrangement of 4b, 
we explored the scope of the reaction. Ring-expansion of the 5-
membered indoline derivative 3a required more forcing 
conditions (4 hours at 120 °C), but yielded the corresponding 9-
membered product 4a in excellent yield. Rearrangements of 
larger rings (6- to 8-membered) were even cleaner, providing the 
corresponding 10- to 12-membered compounds 4b-d in 
excellent yields after short reaction times. The reaction showed 
good tolerance to halogen substituents, with fluoro-, bromo-, and 
chloro-substituted products 4e-j formed without dehalogenation. 
The reaction conditions were fully compatible with the 
metabolically stable, lipophilic trifluoromethoxy group of 4k.[16] 
Moderate steric hindrance around the reactive centers was 
tolerated, as demonstrated by products 4e, 4f and 4l. Products 
with functionalized rings were made by rearrangement of staring 
materials containing alternative heterocycles. Ring opening of 
dibenzazepine leads to benzop-fused product 4m in near-
quantitative yield. Heterocycles containing an additional nitrogen 
atom, namely benzodiazepane and quinoxaline, also 
successfully rearranged, yielding the triaza ring systems of 4n 
and 4o. 
 
Scheme 2. Scope of the ring expansion. Yields of isolated products. [a] 3 
mmol scale. [b] Based on recovered starting material. 
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Further transformations of the amide function of the medium-ring 
products were possible. Alkylation of the amide nitrogen with 
methyl iodide gave 5 in 77% yield, and reduction of the carbonyl 
with a solution of borane dimethyl sulfide in THF, gave the more 
lipophilic diamine 6. 
Table 2. Crystal structures of 4a-d, and selected structural data. 
 
Cpd. dN-H-N / Å θAr–CO / ° δNH / ppm ΔδNH/%DMSO / ppm %–1 
4a 2.42	 54	 5.87	 0.025	
4b 2.72	 58	 6.46	 0.031	
4c 2.47	 42	 7.72	 0.004	
4d 1.95	 1.3	 9.10	 -0.014	
 
The conformation and dynamics of the medium-ring products 
were investigated in the solid state and in solution. Crystals 
suitable for X-ray analysis were obtained for each ring size, 
revealing the solid-state conformation of compounds 4a-d and 4l 
(Table 2).[17] The relative difficulty of synthesizing compound 4a 
can be explained by the deviation from planarity in its amide 
group: the sum of the bond angles at nitrogen (344.4°) and its 
pyramidalization (χN = 47.8°) indicate significant sp3 character at 
the amide nitrogen.[18] Moreover, while the C–N bond torsion 
angle is moderate (τ = 23.4°), the dihedral angle between the 
amide group and the adjacent aromatic ring (θAr–CO = 54°) 
restricts delocalization. 
A clear trend was observed as the ring size increased from 
10 to 11 to 12. The N-H-N distance shortened from 2.72 to 1.95 
Å with larger rings, with the Ar–CO dihedral angle approaching 
0° in the 12-membered ring, permitting conjugation between the 
amide and the aromatic ring. This behavior suggested a 
transannular hydrogen bond, a characteristic of interest for the 
development of bioactive molecules with ‘hidden 
hydrophilicity’.[5c,19] 
The downfield shift of the N-H signal in the 1H NMR 
spectra of the products 4 in CDCl3 from 6.46 to 9.10 ppm with 
increasing ring size also indicated a progressively stronger 
hydrogen bond. Titration with DMSO-d6 of solutions of 
compounds 4a-d in CDCl3 shifted the N-H signal in the 1H NMR 
spectrum of 9- and 10-membered compounds 4a and 4b 
strongly downfield (Table 2, final column). Hardly any shift was 
observed for 11-membered compound 4c; 12-membered 
compound 4d displayed a moderate upfield shift. These 
observations suggest that the transannular intramolecular 
hydrogen bond evident in the solid state persists in solution, 
increasing in strength with larger rings.[20] 
1H NMR of compounds 4a-l showed diastereotopic signals 
for the methylene groups within the ring, indicating that these 
heterocycles adopt chiral ground states whose enantiomeric 
conformations interconvert slowly on the NMR time scale.[21,22] 
We determined the rate constants of enantiomerisation of 
compounds 4a-d and 4l by Variable Temperature Exchange 
Spectroscopy (VT-EXSY), as summarized in Table 3 (See SI for 
details). Apart from 4a, with its distorted amide, larger rings were 
significantly more flexible: 12-membered ring 4d inverted more 
than 2000 times faster than 10-membered 4b in CDCl3, which 
may even exist as two atropisomeric enantiomers at 
temperatures around 0 °C. The rates to enantiomerisation were 
up to tenfold faster in polar solvents such as DMSO-d6, with 
barriers to enantiomerisation in larger rings 4c and 4d being 
more sensitive to solvent polarity than in 4b. 
 
Table 3. Rates of conformational enantiomerisation of 4a-d in various 
solvents. 
Cpd.	 Solvent	 kenant	/	s	 ΔG
‡	/	kJ	mol–1	[a]	 τ1/2	/	s	
[b]	
4a DMSO-d6/CD3OD[c] – – – 
 Toluene-d8 0.0082 84.9 42.3 
4b DMSO-d6 0.0074 85.1 47.1 
 CDCl3 0.0019 88.5 180.9 
4c DMSO-d6 0.16 77.5 2.1 
 CDCl3 0.016 83.2 21.6 
4d CD3OD 30.7 64.5 0.011 
 CDCl3 4.6 69.2 0.076 
4l DMSO-d6 0.049 80.4 7.0 
 CDCl3 0.031 81.6 11.1 
[a]	 Free	 energy	 of	 enantiomerisation	 calculated	 at	 298	 K.	 [b]	 Half-life	 for	
racemisation	at	298	K.	[c]	Peak	overlap	precludes	calculation	in	either	solvent.	
1H NMR indicated another distinctive feature of 4a: it exists as a 
pair of inequivalent diastereoisomeric conformers whose 
proportions vary with the solvent, with less of the minor 
conformer in toluene-d8 or CDCl3 (ratios of 7:1 and 6:1) than in 
CD3OD and DMSO-d6 (ratios of 3:1). Cross-peaks for the 
interconversion of the diastereoisomeric conformers were 
evident by EXSY NMR, and the barriers to their interconversion 
in both CD3OD and toluene-d8 were calculated using the Eyring 
equation (Table 4). While the rate at which the minor 
diastereomer converts to the major shows little dependence on 
solvent, the rate of the reverse process is strongly solvent-
dependent, and is three times as fast in CD3OD. This suggests 
that the major conformer owes its relative stability to an 
additional intramolecular hydrogen bond which is destabilised by 
hydrogen bonding solvents.  
These diastereoisomeric conformers probably arise from 
the two alternative relative orientations of Ar–CO and Ar–N 
bonds of the adjacent secondary amide and tertiary amine 
groups. Clear evidence that twisting in these bonds can lead to 
diastereoisomeric conformers came from 11-membered ring 4l, 
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which also displays two diastereoisomeric conformers in its 1H 
NMR spectrum.[23,24] The crystal structure of compound 4l 
(Scheme 3) shows a more or less perpendicular arrangement in 
the amide Ar—CO bond, and a strong downfield shift of the N-H 
signal from 6.12 ppm in CDCl3 to 7.84 ppm in DMSO-d6 
indicates that the intramolecular hydrogen bond in the ground 
state of 4l is weaker than in 4c. However, EXSY NMR shows 
that compound 4l possesses a similar barrier to 
enantiomerisation as compound 4c. The similarity of the rates of 
exchange for enantiomerisation in CDCl3 and DMSO-d6 
suggests that compound 4l adopts in solution a conformation 
similar to the one observed in the solid state, with a 
perpendicular Ar—CO bond. 
1H NMR of compound 4l revealed a mixture of 
diastereoisomeric atropisomers in ratios of 3:1 in toluene-d8, 4:1 
in CDCl3 and 10:1 in CD3OD. This trend, opposed to compound 
4a, shows that despite the perpendicular twist in the amide of 4l, 
the flexibility of the 11-membered ring allows an intramolecular 
hydrogen bond in solution, but only in the minor conformer. The 
rate of interconversion of the diastereomers was calculated 
using EXSY NMR at higher temperatures (Table 4). 
 
Table 4. Diastereomerisation parameters of compounds 4a and 4l. 
Cpd. Solvent kmin-maj[a] 
/ s-1 
kmaj-min[b] 
/ s-1 
ΔG‡min-maj[a] 
/ kJ mol–1 
ΔG‡maj-min[b] 
/ kJ mol–1  
4a	 CD3OD	 0.326	 0.099	 75.8	 78.7	
	 Toluene-d8	 0.306	 0.035	 75.9	 81.3	
4l	 DMSO-d6	 0.00052	 0.00022	 91.7	 93.9	
	 CDCl3	 0.0083	 0.0026	 84.8	 87.8	
Rates and free energies of activation for conversion of [a] minor to major and 
[b] major to minor conformer, at 298 K. 
 
Scheme 3. X-ray crystal structure and conformational dynamics of 4l. 
Unlike compound 4a, diastereomerisation of compound 4l is 
slower than enantiomerisation by a factor of almost 4 in CDCl3 
and up to 100 in DMSO-d6. The rates of diastereomerisation of 
compound 4l (unlike those of enantiomerisation) is strongly 
solvent-dependent. In this case, DMSO-d6 raised the free energy 
of both the forward and reverse exchange relative to CDCl3. 
Because the amide group and the adjacent aromatic ring are 
perpendicular in the ground state, diastereomerisation must 
occur through a transition state in which these two groups are 
coplanar. In non-hydrogen bonding solvent such as CDCl3, the 
barrier to diastereomerisation is lowered by transient 
transannular hydrogen bonding between the amide proton and 
the diarylamine nitrogen. In DMSO-d6, the relative energy of 
transition state becomes less favorable, decreasing the rate of 
exchange by a 10-fold. Unlike compound 4a, for which 
enantiomerisation occurs through stepwise bond rotation, these 
higher values for diastereomerisation compared to 
enantiomerisation suggest that racemisation of compound 4l 
occurs through geared rotation of the Ar—CO and the Ar—N 
bonds (Scheme 3). 
To conclude, we used Smiles rearrangement of 
anthranilamides to yield medium-size heterocyclic analogues of 
dibenzodiazepines. Microwave heating reduces reaction time to 
15 minutes, providing 9- to 12-membered rings in excellent 
yields. The reaction tolerates sensitive functional groups, and 
can be performed in a ‘green solvent’. A transannular hydrogen 
bond in the products provides the structures with ‘hidden 
hydrophilicity’. The strength of this hydrogen bond, which 
governs the stereodynamic properties of the medium-ring 
heterocycles, is modulated either by ring size or introduction of 
steric hindrance close to the amide group, making this class of 
compounds a versatile tool of drug development. 
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